New combo shows promise for tough bile duct cancer

NCT ID NCT03785873

Completed Disease control Sponsor: University of Michigan Rogel Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a combination of an immunotherapy drug (nivolumab) and chemotherapy drugs (nanoliposomal-irinotecan, 5-fluorouracil, and leucovorin) in 34 people with advanced biliary tract cancer that had worsened after initial treatment. The goal was to see if the combo could shrink tumors or slow cancer growth. While not a cure, the approach aims to give patients more time and better control over the disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BILIARY TRACT CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

biliary tract cancer Biliary Tract Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BILIARY TRACT CANCER

Contacts and locations

Show contact details

Locations

Cancer and Hematology Centers of Western Michigan

Grand Rapids, Michigan, 49503, United States
University of Michigan Rogel Cancer Center

Ann Arbor, Michigan, 48109, United States
University of Utah

Salt Lake City, Utah, 84132, United States
University of Wisconsin

Madison, Wisconsin, 53705, United States
Virginia Mason

Seattle, Washington, 98101, United States